中国实验血液学杂志最新文献

{"title":"[Efficacy and Safety of BeEAM, a Conditioning Regimen for Autologous Stem Cell Transplantation in Malignant Lymphoma].","authors":"Feng-Quan Gou, Jia-Jia Li, Jun-Feng Zhu, Kai Zhu, Li-Li Han, Meng Wang, Feng Zhang","doi":"10.19746/j.cnki.issn.1009-2137.2025.01.036","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.01.036","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the efficacy and safety of the conditioning regimen BeEAM (bendamustine+et-oposide+cytarabine+melphalan) in autologous stem cell transplantation (ASCT) for patients with malignant lymphoma.</p><p><strong>Methods: </strong>The clinical data of 20 patients with malignant lymphoma who underwent ASCT after conditioning with BeEAM regimen from January 2021 to December 2022 in the First Affiliated Hospital of Bengbu Medical University were collected, and the clinical characteristics before transplantation, conditioning-related toxicity, hematopoietic reconstitution after transplantation, and therapeutic effects were analyzed. 67 patients with malignant lymphoma who did not undergo ASCT during the same period were selected as the control group, and the 1-year progression-free survival (PFS) rate and overall-survival (OS) rate between the ASCT group and the non-ASCT group were compared.</p><p><strong>Results: </strong>15 cases achieved complete remission (CR) and 5 cases achieved partial remission (PR) before transplantation in ASCT group. During the conditioning process of patients in the ASCT group, 14 cases experienced gastrointestinal adverse reactions, 13 cases experienced neutropenic fever, 10 cases experienced oral mucositis, 2 cases experienced abnormal liver function, and only 1 case experienced acute renal injury. All the adverse reactions resolved after symptomatic treatment. After transplantation, 19 cases achieved hematopoietic reconstitution, and only one case had poor platelet engraftment. The median time of peripheral white blood cell (WBC) engraftment was 9 (9-16) days, and the median time of platelet engraftment was 12 (10-23) days. By the end of follow-up, there were no transplant-related deaths. The 1-year PFS rates in the ASCT group and the non-ASCT group were 94.4% and 68.5%, respectively; The 1-year OS rates were 94.4% and 83.5%, respectively. The median PFS and OS time for both groups were not reached. The PFS in the ASCT group was significantly better than that in the non-ASCT group (<i>P</i> < 0.05), and there was no significant difference in OS between the two groups ( <i>P</i> >0.05).</p><p><strong>Conclusion: </strong>BeEAM regimen is safe and effective as a conditioning treatment for ASCT in patients with malignant lymphoma, with tolerable adverse reactions, controllable non-hematological toxicity, smooth hematopoietic reconstitution, and considerable short-term efficacy. However, further follow-up is required to evaluate its long-term efficacy.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 1","pages":"241-245"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143524592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Mutation Detection of Plasma Circulating Tumor DNA Associated with Multiple Myeloma].","authors":"Qing-Zhao Li, Hai-Mei Chen, Zhao-Hui Yuan, Chan-Juan Shen, Guo-Yu Hu, Juan Peng","doi":"10.19746/j.cnki.issn.1009-2137.2025.01.020","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.01.020","url":null,"abstract":"<p><strong>Objective: </strong>To explore the clinical significance of 26 circulating tumor DNA (ctDNA) associated with multiple myeloma (MM) in peripheral blood of new diagnosed patients.</p><p><strong>Methods: </strong>We conducted a study to detect 26 ctDNA mutations in the peripheral blood of 31 newly diagnosed multiple myeloma (NDMM) patients.</p><p><strong>Results: </strong>Among the 31 NDMM patients, the ctDNA detection rate was 93.55%, significantly higher than that of FISH and chromosome screening methods. The most frequently mutated genes in NDMM were <i>ACTG1</i> and <i>GNAS</i>. Notably, <i>ACTG1</i> mutations were exclusive to NDMM patients, furthermore, resulted from the missense mutation of the exon 4. <i>ACTG1</i> was the gene most frequently co-mutated with others. All patients with <i>ACTG1</i> mutations were surviving, and there was a positive correlation between <i>ACTG1</i> mutation and the survival of patients. <i>GNAS</i> mutations were confined to exon 1.</p><p><strong>Conclusion: </strong>The detection rate of ctDNA sequencing in peripheral blood of NDMM patients was higher than that in bone marrow. <i>ACTG1</i> and <i>GNAS</i> genes have a guiding role in the prognosis of newly diagnosed patients.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 1","pages":"142-149"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143524688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Prognostic Value of Plasma Fibrinogen Levels in Patients with Diffuse Large B-Cell Lymphoma].","authors":"Bing Zhang, Lin Lin, Jian-Min Ji, Yu Wu, Qun Shen","doi":"10.19746/j.cnki.issn.1009-2137.2025.01.016","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.01.016","url":null,"abstract":"<p><strong>Objective: </strong>To assess the prognostic significance of plasma fibrinogen（FIB） levels in patients of diffuse large B-cell lymphoma(DLBCL).</p><p><strong>Methods: </strong>We retrospectively analyzed 203 newly diagnosed with DLBCL patients who met the study requirements from November 2016 to May 2024. Based on the receiver operating characteristic (ROC) curve analysis of plasma FIB levels during diagnosis, the critical value of FIB was determined, and patients were divided into high FIB and low FIB groups. The clinical characteristics and relevant laboratory indicators of two groups were compared. The impact of plasma FIB levels on overall survival (OS) were evaluated using Kaplan-Meier curves as well as univariate and multivariate Cox regression analysis. The differences in FIB and other laboratory indicators under different disease states were compared.</p><p><strong>Results: </strong>According to the ROC curve, the optimal cut-off value of FIB was 3.49 g/L. Compared with the high FIB group (>3.49 g/L), the low FIB group (≤3.49 g/L) had a significant decrease in neutrophil count (ANC) (<i>P</i> =0.001) and platelet count (PLT) (<i>P</i> =0.027), and a significant increase in prealbumin (PA) (<i>P</i> =0.001). A high FIB level was associated with decreased OS (<i>P</i> =0.005). Univariate analysis results showed that FIB had an impact on survival of patients(<i>HR</i>＝2.031，95%<i>CI</i> : 1.221-3.375, <i>P</i> =0.006). Multivariate analysis showed that higher FIB level was an independent adverse prognostic factor affecting patients survival （<i>HR</i>＝2.684， 95%<i>CI</i> :1.478-4.875, <i>P</i> =0.001）. Compared with patients with newly diagnosed or recurrent DLBCL, patients with complete remission showed a significant decrease in FIB (<i>P</i> _ND < 0.001, <i>P</i> _R=0.001) and ANC (<i>P</i> _ND < 0.001, <i>P</i> _R=0.021), as well as an increase in albumin (ALB) (<i>P</i> _ND < 0.001, <i>P</i> _R=0.018) and PA (<i>P</i> _ND < 0.001, <i>P</i> _R < 0.001).</p><p><strong>Conclusion: </strong>Elevated FIB is a poor prognostic factor for DLBCL patients. The plasma FIB level is correlated with laboratory indicators such as ANC, PLT, PA, and disease status in DLBCL patients. Dynamic monitoring can assist in the early detection of changes in the condition.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 1","pages":"114-120"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143524758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Analysis of Coagulation Changes and Influencing Factors during Treatment of Acute Promyelocytic Leukemia].","authors":"Zhen-Zhu Chen, Tao Liu, He-He Guo, Wen-Wen Ren, Kai Wang, Ying-Xu Pang","doi":"10.19746/j.cnki.issn.1009-2137.2025.01.007","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.01.007","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;To analyze the changes in coagulation during the treatment of acute promyelocytic leukemia (APL) and explore the influencing factors of coagulation in patients with APL.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;Data of 166 APL patients admitted to our hospital from November 2018 to May 2023 were retrospectively analyzed, and the changes of various clinical indicators before and during treatment were compared. 166 APL patients were divided into abnormal coagulation group (&lt;i&gt;n&lt;/i&gt; =115) and normal coagulation group (&lt;i&gt;n&lt;/i&gt; =51) according to whether they experienced coagulation dysfunction. The basic information, clinical data and laboratory indicators of the two groups were compared. Multivariate logistic regression analysis was used to screen risk factors for coagulation dysfunction and established logistic regression model. Then we developed a neural network model and ranked the importance of the influencing factors, and used receiver operating characteristic (ROC) curves to evaluate the predictive performance of the two models.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;The comparative results of various clinical indicators in 166 APL patients before and during treatment showed that systolic blood pressure (SBP), diastolic blood pressure (DBP), total cholesterol (TC), triacylglycerol (TG), low-density lipoprotein cholesterol (LDL-C), estimated glomerular filtration rate (eGFR), platelet (PLT) and fibrinogen (FIB) were significantly increased during the treatment (&lt;i&gt;P&lt;/i&gt; &lt; 0.05), while glycosylated hemoglobin (HbA1c), high density lipoprotein cholesterol (HDL-C), blood urea nitrogen (BUN), serum creatinine (SCr), high-sensitivity C reactive protein (hs-CRP), IL-6, TNF-α, TGF-β, white blood cells (WBC), absolute neutrophil count (ANC), prothrombin time (PT), activated partial thromboplastin time (APTT), D-dimer (D-D), fibrinogen degradation products (FDP) and lactate dehydrogenase (LDH) were significantly decreased during the treatment (&lt;i&gt;P&lt;/i&gt; &lt; 0.05). The proportion of patients with hemorrhage and high-risk APL in the abnormal coagulation group was significantly higher than that in the normal coagulation group (&lt;i&gt;P&lt;/i&gt; &lt; 0.05). The levels of IL-6, TNF-α, WBC, ANC, D-D, FDP and LDH in the abnormal coagulation group were significantly higher than those in the normal coagulation group (&lt;i&gt;P&lt;/i&gt; &lt; 0.05). The influencing factors selected by univariate analysis were incorporated into logistic regression analysis and neural network model to predict the risk of coagulation dysfunction in APL patients. ROC curves showed that the AUC of the two models were 096 and 0.908, the sensitivity were 0.824 and 0.892, the specificity were 0.940 and 0.904, the Youden index were 064 and 0.796, and the accuracy were 0.882 and 0.898, respectively.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;High risk stratification, hemorrhage, elevated WBC, LDH, ANC and FDP levels are independent risk factors for coagulation dysfunction in APL patients. The logistic regressio","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 1","pages":"45-53"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143524881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Analysis of Influencing Factors and Establishment of Nomogram Model of Differentiation Syndrome in Patients with Acute Promyelocytic Leukemia].","authors":"Yi-Fan Yao, Li-Xia Hao, Lin-Hua Yang","doi":"10.19746/j.cnki.issn.1009-2137.2025.01.009","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.01.009","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the influencing factors of differentiation syndrome (DS) during induction chemotherapy for acute promyelocytic leukemia (APL), and establish a prediction model for DS in newly diagnosed APL patients, in order to guide clinical treatment.</p><p><strong>Methods: </strong>The clinical data of 324 newly diagnosed APL patients were retrospectively analyzed, and the patients were divided into DS group and non-DS group according to whether or not DS was present. Statistically significant factors from comparison of the two groups were selected and included in univariate and multivariate logistic regression to explore the influencing factors of DS in APL. R software was used to build the nomogram model, Bootstrap method was used for internal verification, and concordance index (C-index) and calibration curve were used to evaluate the accuracy of the model.</p><p><strong>Results: </strong>The incidence of DS in 324 patients with newly diagnosed APL was 30.86% (100/324). Univariate logistic regression analysis showed that high risk, delayed retinoic acid, no hormonal prophylaxis, combined with disseminated intravascular coagulation, increased white blood cell count (WBC) at initial diagnosis and neutrophil count, prothrombin prolongation, decreased fibrinogen and albumin (ALB), increased proportion of bone marrow original cells, increased proportion of peripheral blood original cells, and increased peak of WBC after chemotherapy were risk factors for DS in newly diagnosed APL patients (all <i>P</i> < 0.01). Multivariate logistic regression analysis showed that the increased peak value of WBC after chemotherapy, prophylactic use of hormone, and ALB level were independent factors influencing the occurrence of DS in newly diagnosed APL patients (all <i>P</i> < 0.01). The C-index of DS in APL predicted by the nomogram model was 0.847(95%<i>CI</i> : 0.786-0.908). The calibration curve showed that the nomogram was in good agreement with the actual incidence of DS.</p><p><strong>Conclusion: </strong>The independent influencing factors of DS in newly diagnosed APL are the increased peak value of WBC after chemotherapy, ALB and prophylactic use of hormone. The nomogram model based on the above factors can predict the risk of DS in APL patients, which is consistent with clinical observation.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 1","pages":"62-68"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143524885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Relationships between Molecular Genetics and Clinical Features of Children with Acute Myeloid Leukemia].","authors":"Fei Long, Hao Xiong, Li Yang, Ming Sun, Zhi Chen, Wen-Jie Lu, Shan-Shan Qi, Fang Tao, Lin-Lin Luo, Jing-Pei Chen","doi":"10.19746/j.cnki.issn.1009-2137.2025.01.010","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.01.010","url":null,"abstract":"<p><strong>Objective: </strong>To analyze the molecular genetic spectrum of children with acute myeloid leukemia (AML), and explore its correlation with clinical characteristics and prognosis.</p><p><strong>Methods: </strong>The clinical and molecular genetic data of 116 children with newly diagnosed AML in Wuhan Children's Hospital from September 2015 to August 2022 were retrospectively analyzed. The Fisher's exact test was used to analyze the correlation of gene mutations with clinical features, and Kaplan-Meier curve was used to analyze the influences of gene mutations on the prognosis.</p><p><strong>Results: </strong><i>NRAS (22%), KRAS</i> (14.9%), and <i>KIT</i> (14.7%) mutations were the most common genetic abnormalities in 116 children with AML. Children with <i>KIT, CEBPA</i> and <i>GATA2</i> mutations showed a higher median onset-age than those without mutations (all <i>P</i> < 0.05). Children with <i>FLT3-ITD</i> mutation exhibited a higher white blood cell count at initial diagnosis compared to those without mutations (<i>P</i> < 0.05). Children with <i>ASXL2</i> mutation had lower platelet count and hemoglobin at initial diagnosis than those without mutations (both <i>P</i> < 0.05). <i>KIT</i> mutations were often co-occurred with t(8;21)(q22;q22). There was no significant relationship between gene mutation and minimal residual disease (MRD) remission rate after the first and second induction therapy (<i>P</i> >0.05). <i>KIT</i> and <i>NRAS</i> mutations were not associated with prognosis significantly (<i>P</i> >0.05). The overall survival (OS) rates of children with <i>CEBPA</i> and <i>FLT3-ITD</i> mutations were superior to those without mutations, but the differences were not statistically significant (<i>P</i> >0.05). The 3-year OS rate of 61 children treated by allogeneic hematopoietic stem cell transplantation was 89.8%, which was significantly higher than 55.2% of those only treated by chemotherapy (<i>P</i> < 0.001).</p><p><strong>Conclusions: </strong>Gene mutations are common in children with AML, and next-generation sequencing can significantly improve the detection rate of gene mutations, which can guide the risk stratification therapy. In addition, <i>FLT3-ITD</i> and <i>KIT</i> mutations may no longer be poor prognostic factors.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 1","pages":"69-74"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143524770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Correlation Analysis of Serum Complement Level and Prognosis in Diagnosis of Aggressive Non-Hodgkin Lymphoma].","authors":"Bin-Bin Ding, Na-Na Li, Bai Dong, Zi-Jian Li","doi":"10.19746/j.cnki.issn.1009-2137.2025.01.014","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.01.014","url":null,"abstract":"<p><strong>Objective: </strong>To explore the relationship between serum complement levels at diagnosis and prognosis in patients with aggressive non-Hodgkin lymphoma(NHL).</p><p><strong>Methods: </strong>The clinical data of 102 patients with aggressive non-Hodgkin lymphoma diagnosed in the First Hospital of Lanzhou University from February 2017 to March 2023 were selected to analyze the correlation between serum complement C3 and C4 levels and prognosis of patients with aggressive NHL at the time of initial diagnosis. The optimal cut-off point of C3 and C4 were obtained by calculating the Jorden index through the receiver operating characteristic（ROC） curve, and 102 patients were divided into low C3 group (C3< 1.07) and high C3 group (C3≥1.07), low C4 group (C4< 0.255) and high C4 group (C4≥0.255). The effects of serum C3 and C4 levels on the prognosis of these patients were analyzed.</p><p><strong>Results: </strong>ROC curve analysis showed that the area under the curve (AUC) of C3 and C4 in predicting the prognosis of aggressive NHL patients was 0.634 (95%<i>CI</i> ：0.525-0.743；<i>P</i> =0.025) and 0.651 (95%<i>CI</i> ：0.541-0.761；<i>P</i> =0.012), respectively. The optimal cut-off points for C3 and C4 were 1.07 and 0.255, respectively. K-M survival analysis showed that groups with high C3 and C4 levels had shorter progression-free survival (PFS) (<i>P</i> =0.0079; <i>P</i> =0.0092) and overall survival (OS) (<i>P</i> =0.021; <i>P</i> =0.021). Multivariate Cox analysis showed that high level serum complement C3 (<i>HR</i>=2.37, 95%<i>CI</i> : 1.07-5.24, <i>P</i> =0.034) and age ≥60 years (<i>HR</i>=2.34, 95%<i>CI</i> : 1.11-4.95, <i>P</i> =0.025) were independent risk factors for PFS in patients with aggressive NHL. High level complement C3 (<i>HR</i>=2.37, 95%<i>CI</i> : 1.09-5.13, <i>P</i> =0.029) and age ≥60 years at diagnosis (<i>HR</i>=2.40, 95%<i>CI</i> : 1.13-5.13, <i>P</i> =0.024) were independent risk factors for OS in patients with aggressive NHL.</p><p><strong>Conclusion: </strong>The level of serum complement C3 at diagnosis is one of the prognostic factors in patients with aggressive NHL.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 1","pages":"101-107"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143524184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Correlation of LncRNA-PVT1 with Prognosis of Children with Acute Lymphoblastic Leukemia].","authors":"Shan-Wei Liu, Yan-Fen Liu, Qing-Hua Meng, Xian-Jun Sun","doi":"10.19746/j.cnki.issn.1009-2137.2025.01.006","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.01.006","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the expression of long non-coding RNA plasmacytoma variant translocation 1 (lncRNA-PVT1) in children with acute lymphoblastic leukemia (ALL) and its correlation with prognosis.</p><p><strong>Methods: </strong>Clinical data of 64 children with ALL were retrospectively analyzed. All children received standardized treatment according to CCLG-ALL-2015 protocol, and their overall survival (OS) was followed up. Bone marrow examination and lncRNA-PVT1 examination were performed before first diagnosis (T1), early intensive therapy (T2), consolidation therapy (T3), delayed intensive therapy (T4), and maintenance therapy (T5). Bone marrow samples of 25 children with thrombocytopenic purpura were collected during the same period as control group. LncRNA-PVT1 expression was compared between ALL group and control group. ALL children were divided into high-risk group and non-high-risk group according to the risk factors at T3, and the expression changes of lncRNA-PVT1 were analyzed. The correlation of lncRNA-PVT1 with clinical features and prognosis of ALL children was analyzed.</p><p><strong>Results: </strong>The expression of lncRNA-PVT1 in ALL children was significantly higher than that in control group (<i>P</i> < 0.001). ROC curve analysis showed that the area under curve (AUC) of lncRNA-PVT1 for ALL diagnosis was 0.919(95%<i>CI</i> : 0.863-0.975), the optimal cut-off value was 1.465, sensitivity was 87.50%, and specificity was 98.80%. ALL children were divided into low lncRNA-PVT1 group (lncRNA-PVT1< 2.18) and high lncRNA-PVT1 group (lncRNA-PVT1≥2.18) according to the median lncRNA-PVT1 value (2.18). The high lncRNA-PVT1 group had higher Day 33 MRD compared with low lncRNA-PVT1 group (<i>P</i> < 0.01). At T3, T4 and T5, the expression of lncRNA-PVT1 in high-risk group was significantly higher than that in non-highrisk group (all <i>P</i> < 0.01). The expression of lncRNA-PVT1 were significantly increased in high-risk group at 5 time points (<i>P</i> < 0.001), while, there was no significant difference in non-high-risk group (<i>P</i> >0.05). The median OS of low lncRNA-PVT1 group was 35(9-37) months, which was significantly higher than 25(5-33) months of high lncRNA-PVT1 group (<i>P</i> < 0.01). Univariate and multivariate Cox regression analysis showed that Day 33 MRD (>10^-2) and lncRNA-PVT1 (≥2.18) were independent risk factors for OS in ALL children (both <i>P</i> < 0.05).</p><p><strong>Conclusion: </strong>LncRNA-PVT1 is involved in the pathogenesis of ALL in children and closely related to the prognosis.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 1","pages":"39-44"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143524534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Inhibitory Effect of Simvastatin Combined with Doxorubicin on Biological Functions of Diffuse Large B-Cell Lymphoma Cells and Its Mechanism].","authors":"Yao Wang, Min-An Zhang, Huan Zhou, Qing-Feng Xue, Wen-Yu Shi, Ya-Ping Zhang","doi":"10.19746/j.cnki.issn.1009-2137.2025.01.012","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.01.012","url":null,"abstract":"<p><strong>Objective: </strong>To explore the effect of simvastatin monotherapy or in combination with doxorubicin on diffuse large B-cell lymphoma (DLBCL) cells and its possible molecular mechanisms.</p><p><strong>Methods: </strong>The differences in the expression levels of genes and proteins related to the mevalonate (MVA) pathway between DLBCL tissues and reactive lymph node hyperplasia tissues were compared via database analysis, as well as their effects on the prognosis. CCK-8 assay was used to detect the effect of simvastatin and doxorubicin on the viability of different subtypes of DLBCL cells, EdU was used to detect cell proliferation, flow cytometry was used to detect apoptosis, and Western blot was used to detect related protein and signaling pathway proteins.</p><p><strong>Results: </strong>The expression levels of MVA pathway-related genes were increased in tumor tissues of DLBCL patients through the TCGA database, and the median overall survival time of DLBCL patients in HMGCR high expression group was shorter (all <i>P</i> < 0.05). Meanwhile, according to The Human Protein Atlas database, HMGCR protein was significantly high expressed in DLBCL tumor tissue compared with normal tissue. The viability of DLBCL cell lines treated with simvastatin or doxorubicin monotherapy was decreased in time- and concentration-dependent manner, and could be further inhibited by simvastatin combined with doxorubicin especially in GCB subtype cell lines. Both simvastatin and doxorubicin could inhibit the proliferation of DLBCL cell lines, and their combination further suppressed dramatically. Both the two drugs promoted apoptosis in DLBCL cell lines, and the apoptosis was further increased after their combination. Compared with monotherapy, the expression of HMGCR protein and apoptosis-related protein Bcl-2 was further decreased but cleaved-caspase3 and Bax increased after combination therapy. Meanwhile, the expression level of phosphorylated proteins in PI3K-Akt pro-survival signaling pathway were decreased especially in GCB subtype cell lines.</p><p><strong>Conclusion: </strong>HMGCR, the protein associated with cholesterol synthesis pathway, is highly expressed in DLBCL tumor tissues and indicates poor prognosis. Simvastatin, a lipid-lowering drug, combined with doxorubicin can further affect the survival of DLBCL tumor cells at the cellular level.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 1","pages":"82-92"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143524682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Role of Total Vitamin D, Total Procollagen Type I Amino-Terminal Propeptide and β-CrossLaps in Multiple Myeloma].","authors":"Mei-E Wang, Ting Su, Xi-Zhe Guo, Rong-Fu Huang, Yu-Yu Zheng, Gen-Wang Chen, Chun-Mei Fan","doi":"10.19746/j.cnki.issn.1009-2137.2025.01.023","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.01.023","url":null,"abstract":"<p><strong>Objective: </strong>To analyze the significance of total vitamin D (tVD), total procollagen type I amino-terminal propeptide (tPINP) and β-CrossLaps (β-CTx) in the staging and prognosis of patients with multiple myeloma (MM).</p><p><strong>Methods: </strong>A total of 54 patients with newly diagnosed MM admitted to the Second Affiliated Hospital of Fujian Medical University from 2020 to 2022 were selected as the observation group (MM group), and 50 healthy persons who underwent physical examinations in our hospital were selected as the control group. The expression levels of tVD, tPINP and β-CTx in the two groups were detected by chemiluminescence method. The differences in the expression levels of tVD, tPINP and β-CTx among MM patients at different ISS stages were analyzed. The expression levels of tVD, tPINP and β-CTx in MM patients with different levels of hemoglobin (Hb), serum calcium (Ca), creatinine (Crea), albumin (ALB), β₂-microglobulin (β₂-MG) and lactate dehydrogenase (LDH) were compared. The correlations between the expression levels of tVD, tPINP, β-CTx and the aforementioned clinical parameters were analyzed, respectively. The relationship between the expression levels of tVD, tPINP, β-CTx and the progression-free survival (PFS) of MM patients was analyzed.</p><p><strong>Results: </strong>The expression level of tVD in the MM group was significantly lower than that in the control group (21.73±14.45 ng/ml <i>vs</i> 30.78±9.94 ng/ml, <i>P</i> =0.022). The expression level of β-CTx in the MM group was significantly higher than that in the control group (1.43±0.99 ng/ml <i>vs</i> 0.53±0.29 ng/ml, <i>P</i> =0.013). The tVD level in MM patients with ISS stage I-II was significantly higher than that of MM patients with ISS stage III (29.50±14.59 ng/ml <i>vs</i> 12.62±7.73 ng/ml, <i>P</i> =0.028), indicating that the higher the ISS stage, the lower the tVD level. The tPINP and β-CTx levels in MM patients with high Ca levels (>2.65 mmol/L) were significantly higher than those in patients with low Ca levels (≤2.65 mmol/L) (<i>P</i> =0.016, <i>P</i> =0.021). The tVD level of MM patients was positively correlated with the ALB level (<i>r</i> =0.570), tPINP was positively correlated with Ca and β₂-MG levels (<i>r</i> =0.791,<i>r</i> =0.673), and β-CTx was positively correlated with tPINP level (<i>r</i> =0.616). The PFS of the low tVD expression group was significantly lower than that of the high tVD expression group (<i>P</i> =0.041).</p><p><strong>Conclusion: </strong>The expression level of tVD is decreased in MM patients, which can be used as an indicator to evaluate the disease stage and prognosis of the patients. The β-CTx expression level is increased in MM patients. tPINP and β-CTx may be correlated with clinical symptoms such as osteolytic lesions and renal function changes in MM patients.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 1","pages":"163-167"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143524819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}